ContraFect Corporation (CFRXQ)
- Previous Close
0.0180 - Open
0.0180 - Bid --
- Ask --
- Day's Range
0.0180 - 0.0180 - 52 Week Range
0.0110 - 2.2100 - Volume
16,265 - Avg. Volume
24,175 - Market Cap (intraday)
192,686 - Beta (5Y Monthly) 0.21
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date Apr 29, 2024 - May 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.00
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York. On December 4, 2023, ContraFect Corporation filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.
www.contrafect.comRecent News: CFRXQ
Performance Overview: CFRXQ
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CFRXQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CFRXQ
Valuation Measures
Market Cap
192.69k
Enterprise Value
-2.67M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.09
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-117.44%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-24.14M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
5.41M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-24.6M
Research Analysis: CFRXQ
Company Insights: CFRXQ
CFRXQ does not have Company Insights